Frank Corbett, medical advertising great, dies

Share this article:
Frank Corbett, medical advertising great, dies
Frank Corbett, medical advertising great, dies

Medical advertising pioneer Frank J. Corbett passed away Wednesday, December 9. He was 92.

Corbett was a founder of the Chicago-based agency network known today as Corbett Accel Healthcare Group and one of the early greats of medical advertising account management.

Growing up in Manhattan, Corbett worked as a delivery boy for Cut Rate Drugs before earning a degree in pharmacy from Columbia University in 1938. After stints as an Upjohn sales rep, a sales exec for chain drugstore Rexall and a marketer for Warner and Lambert, he moved to the Midwest in 1956 and joined the Jordan Sieber agency, leaving six years later to launch his own eponymous shop with his wife, Dolores.

The Corbett agency launched with Westwood Pharmaceuticals as its corner stone client, and shortly added accounts from Baxter, Lakeside and Eaton. The shop pioneered the use of feedback mechanisms in direct mail and new media in details (Super 8 film, in this case, for Beecham's Amoxil), and was ahead of its time in advancing women to positions of authority. Frank J. Corbett, Inc. became the first medical agency to be acquired by a big consumer agency in 1972, when it was bought by BBDO (whose 1986 merger with DDB, in turn, created the Omnicom holding company). The firm became Corbett Accel in 2004, when Corbett Healthcare Group merged with Accel Healthcare Communications.

Corbett retired in 1997, but maintained an office at the shop's Chicago headquarters and came in regularly to keep abreast of business.

In 1998, Corbett was inducted into the Medical Advertising Hall of Fame, where colleagues praised him as “the ‘complete professional' who put his personal knowledge to work for his clients with energy and creativity,” running a “tight ship” but being “known for his warm sense of humor, the friendly work environment he created and his polite, gentlemanly manner.”

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...